Ipamorelin Compounding Pharmacy: How to Read a Certificate of Analysis

What a COA can and cannot settle

A COA is a lot-specific laboratory report: the tests run on a sample from one batch, the method used for each, and the result. It does not make an unapproved drug approved. Ipamorelin is not an FDA-approved drug and is not a component of any approved drug [1][2]. FDA's review found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin; the human studies that exist used intravenous dosing [1][6][7].

Identity

Ipamorelin is a five-amino-acid peptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2 [2]. A useful identity section names the compound, gives that sequence, states the method, and reports mass spectrometry data such as measured molecular mass. Identity from an HPLC retention time alone gives no structural data to compare with the sequence.

Purity and impurities

FDA's category 2 entry for ipamorelin acetate cites possible immunogenicity for certain routes of administration from aggregation and peptide-related impurities [3]. A single purity percentage on a COA does not show whether those concerns have been addressed. Look for the main-peak percentage, each detected impurity and its level, the total impurity figure, the chromatogram, and the method used. With no ipamorelin monograph, there is no compendial purity limit to grade a number against [1][2].

Sterility and endotoxin

For a vial sold for injection, look for lot-specific sterility and bacterial endotoxin results and the methods used. Those results address contamination of that lot, not whether ipamorelin is safe to inject.

Red flags in the report itself

• Identity by retention time only, with no mass data.
• No lot or batch number tying the report to the vial.
• No chromatogram, or a purity figure with no method stated.
• A testing laboratory sharing a name, address or ownership with the seller.

Where the regulatory status stands

FDA lists ipamorelin acetate among bulk substances that may present significant safety risks — category 2 — for large outsourcing facilities; it was added September 29, 2023 and is still listed on the page dated April 22, 2026 [3][4]. For state-licensed pharmacies and physicians it sits in the nominated-but-withdrawn table, and in none of the three categories on the list updated May 14, 2026 [3][8]. On October 29, 2024 FDA's Pharmacy Compounding Advisory Committee voted 0 yes, 12 no, 1 abstention on ipamorelin free base and the same on ipamorelin acetate, citing a lack of information supporting safety and efficacy for growth hormone deficiency and postoperative ileus [5]. Ipamorelin is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [9].